{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:02:57Z","timestamp":1782363777880,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11102-025-01570-9","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:40:28Z","timestamp":1760092828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SAGIT\u00ae, ACRODAT\u00ae, PANOMEN 3\u2026 time to implement tools for management of acromegaly..?"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"S.J.C.M.M Neggers","year":"2008","unstructured":"Neggers S.J.C.M.M., van Aken M.O., de Herder W.W., Feelders R.A., Janssen J.A.M.J.L., Badia X., Webb S.M., van der Lely A.J. (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without Pegvisomant. J Clin Endocrinol Metab 93:3853\u20133859","journal-title":"J Clin Endocrinol Metab"},{"key":"1570_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.02214","volume":"155","author":"SM Webb","year":"2006","unstructured":"Webb SM, Badia X, Surinach NL, Spanish G (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:269\u2013277. https:\/\/doi.org\/10.1530\/eje.1.02214","journal-title":"Eur J Endocrinol"},{"key":"1570_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11102-015-0681-2","volume":"19","author":"Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S, Group SI","year":"2016","unstructured":"Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S, Group SI (2016) SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice\u2013development and results from a pilot study. Pituitary 19:39\u201349. https:\/\/doi.org\/10.1007\/s11102-015-0681-2","journal-title":"Pituitary"},{"key":"1570_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11102-019-00977-5","volume":"22","author":"A Giustina","year":"2019","unstructured":"Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S (2019) Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT(R) validation study. Pituitary 22:476\u2013487. https:\/\/doi.org\/10.1007\/s11102-019-00977-5","journal-title":"Pituitary"},{"key":"1570_CR5","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/clinem\/dgab536","volume":"106","author":"A Giustina","year":"2021","unstructured":"Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S (2021) International multicenter validation study of the SAGIT(R) instrument in acromegaly. J Clin Endocrinol Metab 106:3555\u20133568. https:\/\/doi.org\/10.1210\/clinem\/dgab536","journal-title":"J Clin Endocrinol Metab"},{"key":"1570_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11102-025-01543-y","volume":"28","author":"F Dassie","year":"2025","unstructured":"Dassie F, Ceccato F, Sartorato P, Trevisan V, Davi MV, Camerini S, De Menis E, Scaroni C, Maffei P (2025) ACRODAT and SAGIT for the assessment of disease activity in acromegaly: a multicenter study of the Veneto region in Italy. Pituitary 28:76. https:\/\/doi.org\/10.1007\/s11102-025-01543-y","journal-title":"Pituitary"},{"key":"1570_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.23736\/S2724-6507.22.03888-X","volume":"50","author":"E Gezer","year":"2025","unstructured":"Gezer E, Cetinarslan B, Canturk Z, Selek A, Sozen M, Koksalan D, Bekiroglu A, Anik I, Ceylan S (2025) May the SAGIT(R) instrument be used as a preoperative prognostic tool in patients with acromegaly? Minerva Endocrinol (Torino) 50:24\u201331. https:\/\/doi.org\/10.23736\/S2724-6507.22.03888-X","journal-title":"Minerva Endocrinol (Torino)"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.eprac.2022.04.002","volume":"28","author":"R Herman","year":"2022","unstructured":"Herman R, Goricar K, Janez A, Jensterle M (2022) Clinical applicability of Patient- and Clinician-Reported outcome tools in the management of patients with acromegaly. Endocr Pract 28:678\u2013683. https:\/\/doi.org\/10.1016\/j.eprac.2022.04.002","journal-title":"Endocr Pract"},{"key":"1570_CR9","doi-asserted-by":"publisher","unstructured":"Sawicka-Gutaj N, Ziolkowska P, Biczysko A, Erampamoorthy A, Ziemnicka K, Ruchala M (2023) The potential utility of the SAGIT instrument in the clinical assessment of patients with acromegaly, a large single-centre study. Sci Rep 13(3286). https:\/\/doi.org\/10.1038\/s41598-023-29957-3","DOI":"10.1038\/s41598-023-29957-3"},{"key":"1570_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jocn.2022.03.020","volume":"99","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Wei W, Guo X, Wang Z, Deng K, Lian W, Yang B, Xing B (2022) Bone metabolic indices: promising predictors for assessing acromegaly. J Clin Neurosci 99:239\u2013243. https:\/\/doi.org\/10.1016\/j.jocn.2022.03.020","journal-title":"J Clin Neurosci"},{"key":"1570_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","volume":"20","author":"AJ van der Lely","year":"2017","unstructured":"van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jorgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20:692\u2013701. https:\/\/doi.org\/10.1007\/s11102-017-0835-5","journal-title":"Pituitary"},{"key":"1570_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12020-021-02900-0","volume":"75","author":"M Marazuela","year":"2022","unstructured":"Marazuela M, Blanco C, Bernabeu I, Menendez E, Villar R, Paja M, Sampedro-Nunez M, Samaniego M, Diaz-Munoz ML, Sanchez-Cenizo L (2022) Acromegaly disease activity according to ACRODAT(R), a cross-sectional study in spain: ACROVAL study. Endocrine 75:525\u2013536. https:\/\/doi.org\/10.1007\/s12020-021-02900-0","journal-title":"Endocrine"},{"key":"1570_CR13","doi-asserted-by":"publisher","first-page":"1516899","DOI":"10.3389\/fendo.2025.1516899","volume":"16","author":"C Gandhi","year":"2025","unstructured":"Gandhi C, Denis MC, Holmes D, Rivera J, van Uum S, Ezzat S, Chik C (2025) Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly. Front Endocrinol (Lausanne) 16:1516899. https:\/\/doi.org\/10.3389\/fendo.2025.1516899","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1570_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s40618-022-01782-x","volume":"45","author":"S Camerini","year":"2022","unstructured":"Camerini S, Wennberg A, Adriani M, Martin B, Vettor R, Maffei P, Dassie F (2022) Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management. J Endocrinol Invest 45:1823\u20131834. https:\/\/doi.org\/10.1007\/s40618-022-01782-x","journal-title":"J Endocrinol Invest"},{"key":"1570_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, Strasburger C, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF (2023) Pilot study to define criteria for pituitary tumors centers of excellence (PTCOE): results of an audit of leading international centers. Pituitary 26:583\u2013596. https:\/\/doi.org\/10.1007\/s11102-023-01345-0","journal-title":"Pituitary"},{"key":"1570_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-024-01460-6","volume":"27","author":"AL Friedel","year":"2024","unstructured":"Friedel AL, Schock L, Siegel S, Fritz AH, Unger N, Harbeck B, Dammann P, Kreitschmann-Andermahr I (2024) Shared decision-making and detection of comorbidities in an online acromegaly consultation with and without the acromegaly disease activity tool ACRODAT((R)) using the simulated person approach. Pituitary 27:545\u2013554. https:\/\/doi.org\/10.1007\/s11102-024-01460-6","journal-title":"Pituitary"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11102-018-00933-9","volume":"22","author":"Y Jackson","year":"2019","unstructured":"Jackson Y, Flood E, Rhoten S, Janssen EM, Lundie M (2019) AcroVoice: eliciting the patients\u2019 perspective on acromegaly disease activity. Pituitary 22:62\u201369. https:\/\/doi.org\/10.1007\/s11102-018-00933-9","journal-title":"Pituitary"},{"key":"1570_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2213-8587(23)00382-0","volume":"12","author":"KKY Ho","year":"2024","unstructured":"Ho KKY, Fleseriu M, Wass J, Katznelson L, Raverot G, Little AS, Castano JP, Reincke M, Lopes MB, Kaiser UB, Chanson P, Gadelha M, Melmed S (2024) A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet Diabetes Endocrinol 12:209\u2013214. https:\/\/doi.org\/10.1016\/S2213-8587(23)00382-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1570_CR19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf252","author":"M Araujo-Castro","year":"2025","unstructured":"Araujo-Castro M, Menendez Torre E, Aida CL, Garcia-Centeno R, Gonzalez L, Idrobo C, Achote E, Irigaray Echarri A, Rodriguez-Argullo MDM, Paja M, Guerrero-Perez F, Castano JP, Dolores Ollero Garcia M, Novo-Rodriguez C, Tenorio-Jimenez C, Villar-Taibo R, Bernabeu I, Diaz-Lopez E, Calatayud M, Alvarez-Escola C, Martin-Rojas P, Recio-Cordova JM, Aulinas A, Asla Roca Q, Aviles MD, Lopez Mezquita E, Fernandez Argueso M, Gonzalez Molero I, Ruz-Caracuel I, Aldecoa I, Garcia J, Martinez-Saez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B (2025) Validation and limitations of the PANOMEN-3 predictive model for tumor recurrence and progression in pituitary tumors. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf252","journal-title":"J Clin Endocrinol Metab"},{"key":"1570_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04292-x","author":"A Mondin","year":"2025","unstructured":"Mondin A, Bovo G, Barbot M, Fleseriu M, Denaro L, Scaroni C, Ceccato F (2025) PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study. Endocrine. https:\/\/doi.org\/10.1007\/s12020-025-04292-x","journal-title":"Endocrine"},{"key":"1570_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ejendo\/lvaf122","volume":"193","author":"P Fookeerah","year":"2025","unstructured":"Fookeerah P, Varikatt W, Shingde M, Dexter MAJ, Lau SL, McCormack A, McLean M (2025) Assessing the clinical application of the PANOMEN 3 classification in a large cohort of pituitary tumors. Eur J Endocrinol 193:56\u201364. https:\/\/doi.org\/10.1093\/ejendo\/lvaf122","journal-title":"Eur J Endocrinol"},{"key":"1570_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11102-025-01534-z","volume":"28","author":"A Giustina","year":"2025","unstructured":"Giustina A, Giustina A (2025) Artificial intelligence in acromegaly: Why, when and how. Pituitary 28:66. https:\/\/doi.org\/10.1007\/s11102-025-01534-z","journal-title":"Pituitary"},{"key":"1570_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11102-025-01515-2","volume":"28","author":"HA Rashwan","year":"2025","unstructured":"Rashwan HA, Marqu\u00e9s-Pamies M, Ruiz S, Gil J, Asensio-Wandosell D, Mart\u00ednez-Mombl\u00e1n M-A, V\u00e1zquez F, Salinas I, Ciriza R, Jord\u00e0 M, Chanson P, Valassi E, Abdelnasser M, Puig D, Puig-Domingo M (2025) Acromegaly facial changes analysis using last generation artificial intelligence methodology: the acroface system. Pituitary 28:50. https:\/\/doi.org\/10.1007\/s11102-025-01515-2","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01570-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01570-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01570-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:46:54Z","timestamp":1765961214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01570-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01570-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"20 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PC. has received unrestricted research and educational grants from Ipsen, Advanz, Recordati and Pfizer as Head of the Department of Endocrinology and Reproductive Diseases, Assistance Publique-H\u00f4pitaux de Paris- Universit\u00e9 Paris-Saclay. PC has served as investigator (principal or coordinator) for clinical trials funded by Pfizer, Ipsen, Crinetics, Debiophram. PC is member of Advisory Boards from Ipsen, Pfizer, Crinetics, Recordati. PC gave lectures for Ipsen, Recordati and Pfizer. All the fees and honoraria are paid to his Institution or Research Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"110"}}